Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 386,240 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 386,240 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the completion of the transaction, the insider directly owned 1,019,658 shares in the company, valued at $22,442,672.58. This trade represents a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 3.2%

Shares of ADPT traded down $0.68 on Tuesday, reaching $20.82. The company’s stock had a trading volume of 2,439,820 shares, compared to its average volume of 2,277,637. Adaptive Biotechnologies Corporation has a twelve month low of $9.96 and a twelve month high of $22.80. The stock has a market capitalization of $3.33 billion, a PE ratio of -63.09 and a beta of 2.07. The firm has a fifty day moving average of $16.24 and a 200-day moving average of $15.90.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) earnings per share. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently bought and sold shares of the company. 1492 Capital Management LLC bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at $1,484,000. Jupiter Asset Management Ltd. grew its stake in shares of Adaptive Biotechnologies by 33.8% during the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after acquiring an additional 91,683 shares during the period. Rhenman & Partners Asset Management AB grew its stake in shares of Adaptive Biotechnologies by 22.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after acquiring an additional 110,000 shares during the period. UBS Group AG grew its stake in shares of Adaptive Biotechnologies by 101.6% during the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after acquiring an additional 257,947 shares during the period. Finally, Westfield Capital Management Co. LP purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth about $65,942,000. 99.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. BTIG Research reissued a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Morgan Stanley reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Finally, Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.